Creatinine Test Market Size

Global Creatinine Test Market Overview

Creatinine Test Market Size was valued at USD 1.042 Billion in 2023. The Creatinine Test market industry is projected to grow from USD 1.2066 Billion in 2024 to USD 3.36 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.66% during the forecast period (2024 - 2032). Growing elderly populations, medical technology advances, and government spending on healthcare to combat the development of renal disorders are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

March 2023 saw the beginning of a new Dignity Health St. Joseph’s Hospital and Medical Center project, based in Phoenix, Arizona, that addresses racial bias by algorithms in early CKD diagnosis and strives to fight health disparities with it. It aims at promoting good health among African Americans (Blacks). The use of racist tools such as estimated glomerular filtration rate (eGFR) can be problematic for kidney disease screening.

Dignity Health St. Joseph’s Hospital and Medical Center is initiating this move in order to introduce an entirely different method of early CKD diagnosis that does not rely on race-based algorithms.

This will greatly alter healthcare outcomes since all the patients will receive accurate diagnoses and appropriate treatments regardless of their color or ethnicity.

In March 2022, Nova Biomedical launched the CE-approved Nova Max Pro Creatinine/eGFR Meter System worldwide (Waltham, MA, USA). The latest development is primarily a potent tool used in outpatient renal care outside hospitals for kidney function screening and also contributes to diagnosis at an earlier stage of these diseases in the same settings. The Nova Max Pro measurement technique performs well when compared to using a glucose meter among diabetics. The CKD-EPI equation uses a fingerstick blood sample to estimate creatinine and estimated glomerular filtration rate (eGFR) without taking venous blood specimens; race may or may not be included in eGFR calculation.

Sysmex America has recently acquired exclusive rights from Siemens Healthcare Diagnostics Inc. to distribute urine chemistry analyzers as well as reagents meant for hospital laboratories and reference laboratories across the North American market under a distribution agreement so as to enhance its urinalysis business within North America.

SphingoTec GmbH invented the pencil-shaped IB10 Sphingotest pen, which is a point-of-care test for Proenkephalin (pencil), in January 2020. By simply testing one’s blood levels, this biomarker enables one to monitor kidney function in real time.

Creatinine Test Market Trends

• Growing kidney related problems is driving the market growth

The rising kidney-related problems are driving market CAGR for Creatinine Tests. Rapid diagnostic methods and procedures to assess creatinine levels in blood and urine are becoming increasingly in demand, causing the market to expand. The need for quick diagnostic tests to measure creatinine levels is being driven by the rapidly rising prevalence of diabetes, which has a detrimental effect on kidney function, the rising prevalence of chronic kidney diseases among the aging population, and the rising number of patients with kidney cancer, glomerulonephritis, and renal failures, among other conditions. An organic acid in muscles called creatine is broken down into creatinine, an endogenous waste product. Clinical laboratories test for creatinine to measure Glomerular Filtration Rate (GFR) and Blood Urea Nitrogen (BUN) to assess kidney health and function.

The cause of death worldwide is kidney disease, specifically Chronic Kidney Disease (CKD). Further complications can be avoided with early diagnosis and appropriate care. The market's major participants are concentrating on producing more high-quality goods to fulfill the increased demand. Furthermore, the market is further fueled by continually rising research activities in the sector. Direct and automation-ready procedures are becoming well-known in research and drug discovery for determining creatinine content in biological samples. The demand for using the creatinine test to diagnose renal diseases is thus rising rapidly. The growing interest in mycobacteria detection in urine and an increase in the number of older adults with kidney disease are two variables that are likely to increase demand for creatinine assays in the coming years. The kidney function tests are anticipated to be driven by the rising prevalence of acute renal injury and chronic kidney disease. CKD refers to structural abnormalities and sustained renal function for at least three months. Significant risk factors for CKD include renal injury and lifestyle disorders. A major global health issue is CKD. It is the primary global cause of illness and mortality. According to WHO data from the preceding nine years, kidney disease is among the top 10 leading causes of death worldwide. Thus, driving the Creatinine Test market revenue.

Creatinine Test Market Segment Insights

Creatinine Test Type Insights

The Creatinine Test Market segmentation, based on test type, includes blood, urine, and creatinine clearance tests. The creatinine clearance tests segment dominated the market, accounting for 35% of market revenue. The gold standard for tracking and calculating glomerular filtration rate is clearance testing. These items contain tests for creatinine and inulin, crucial supplements to conventional diagnostic procedures to get accurate results. Additionally, these tests' top-notch sensitivity and precision guarantee little variance in performance. These items' low prices and simple accessibility on the market encourage greater usage.

Creatinine Test Product Type Insights

The Creatinine Test Market segmentation, based on product type, includes consumables and instruments. The consumables segment dominated the market because more people use consumables for creatinine testing, such as measurement kits, urine test strips, analyzers, cartridges, dipsticks, reagents, etc.

Creatinine Test Application Insights

Based on application, the Creatinine Test Market segmentation includes urinary tract obstruction, renal failure, kidney cancer and glomerulonephritis. The urinary tract obstruction segment dominated the market due to various factors. The primary contributing reason is the rising incidence of urological diseases such as bladder cancer, benign prostatic hyperplasia, urolithiasis, and nephrolithiasis worldwide. Blood clots, calculi, tumors, or sloughed papilla most frequently bring on the urinary blockage. Acute renal colic caused by these blockages manifests with severe flank pain, hematuria, nausea, vomiting, and fever.

Creatinine Test End User Insights

Based on end users, the Creatinine Test Market segment includes hospitals, clinics, diagnostic centers and research institutes. The hospital and clinics category generated the most income (71%). Medical professionals need diagnostic interpretation for subsequent therapy due to increased hospitalization. Typically, diagnostic centers work in tandem with hospitals; as a result, hospitals have their diagnostic infrastructure. Additionally, as healthcare infrastructure continues to be developed, existing hospital facilities are expected to be improved, leading to an expansion of their services and capabilities. Therefore, this growth may increase consumer demand for goods like renal function testing, propelling the market.

Figure 1: Creatinine Test Market, by Distribution channel, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Creatinine Test Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Creatinine Test market will dominate this market, expanding due to rising rates of renal failure, chronic kidney disease, technical advancements in creatinine testing techniques, and improved healthcare infrastructure in the region's nations. Favorable reimbursement practices are another element that boosts industry expansion.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CREATININE TEST MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe holds the second-largest market share for creatinine tests. The key market-driving factors are expanding government backing, rising healthcare spending, and advanced technology. Additionally, the UK Creatinine Test Market had the quickest growth rate in the European region, while the German Creatinine Test Market had the largest market share.

From 2023 to 2032, the Creatinine Test Market in Asia-Pacific will experience the quickest CAGR growth. Major players use various strategies to improve their geographical reach and earning possibilities. Additionally, important aspects driving the market's rapid revenue growth in the Asia Pacific area include the region's growing older population, which is afflicted by chronic ailments like diabetes, kidney issues, etc., and the public's growing familiarity with creatinine testing techniques. Additionally, the Indian Creatinine Test market had the quickest growth rate in the Asia-Pacific region, while China's Creatinine Test market had the greatest market share.

Creatinine Test Key Market Players & Competitive Insights

Leading industry companies are making significant R&D investments to diversify their product offerings, which will drive the Creatinine Test market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Creatinine Test industry must provide affordable products to grow and thrive in a more competitive and challenging market environment.

Local manufacturing to cut operating costs is one of the key business tactics manufacturers use in the global Creatinine Test industry to help clients and expand the market sector. The Creatinine Test industry has offered some of the most significant advantages in recent years. Major players in the Creatinine Test market, including Abbott Laboratories, Sysmex Corporation, and others, are attempting to increase market demand by investing in research and development operations.

I-STAT Alinity, a portable blood chemistry analyzer, was the subject of a non-assignable pilot supplier distribution agreement signed by Abbott HealthTab, Inc. and Abbott. American global medical device and healthcare corporation Abbott Laboratories is headquartered in Abbott Park, Illinois. Wallace Calvin Abbott, a Chicago doctor, began the business in 1888, intending to create well-known drugs; now, it sells branded generic medications, nutritional supplements, medical devices, and diagnostics. In 2013, it formed AbbVie to house its research-based medicines division. In November 2021, Pedialyte, Similac,  Ensure, BinaxNOW, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip are among Abbott's products. The arrangement enables HealthTab to offer Abbott's POC i-STAT Alinity and its accompanying tests for creatinine in Canadian medicine stores, giving patients vital information about their kidney functioning.

Incorporated in Japan with its headquarters in Kobe, Sysmex Corporation operates in the healthcare industry. The Sysmex brand was once known as TOA Medical Electronics, a division of the TOA Corporation, and focused mostly on thermochemistry analyzers when it was first formed in 1978. In 1998, the business changed its name to Sysmex Corporation to capitalize on the recognition of its products. In July 2020, To grow Sysmex's urinalysis business in North America, Sysmex Corporation recently announced that Siemens Healthcare Diagnostics Inc. and Sysmex America, Inc., a subsidiary in the United States, had signed a distribution agreement. This agreement gives Sysmex America the exclusive right to distribute Siemens' urine chemistry analyzers and reagents for hospital and reference laboratory use in the North American market.

Key Companies in the Creatinine Test market include

• Abbott Laboratories


• Abcam Plc


• Acon Laboratories, Inc.


• Nova Biomedical Corporation


• Quest Diagnostic


• Siemens AG


• Thermo Fisher Scientific Inc.


• Roche


• Danaher Corporation.

Creatinine Test Industry Developments

July 2022: The United States Food and Drug Administration (FDA) granted 510(k) clearance to Healthy.io for the Minuteful Kidney test's home use. This one is one of the first smartphone-powered at-home assays to be approved by the FDA to measure albumin to creatinine ratio (ACR).

June 2020: The Point-of-Care (POC) test for Proenkephalin (pencil), the IB10 sphingotest pencil, was introduced by the German company SphingoTec GmbH. Using a routine blood test, this biomarker enables real-time monitoring of kidney function.

Creatinine Test Market Segmentation

Creatinine Test Type Outlook

• Blood Test


• Urine Test


• Creatinine Clearance Test

Creatinine Test Product Type Outlook

• Consumables


• Instruments

Creatinine Test Application Outlook

• Urinary Tract Obstruction


• Renal Failure


• Kidney Cancer


• Glomerulonephritis

Creatinine Test End User Outlook

• Hospital and Clinics


• Diagnostic Centre and Research Institutes

Creatinine Test Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America